Cellectis (CLLS) FCF Payout Ratio (QoQ) (2015 - 2025)
Cellectis (CLLS) FCF Payout Ratio (QoQ) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 186.16% |
| Jun 30, 2025 | 189.05% |
| Sep 30, 2024 | -505.87% |
| Jun 30, 2024 | 109.20% |
| Sep 30, 2023 | 1,508.99% |
| Jun 30, 2023 | 102.07% |
| Sep 30, 2022 | 10.66% |
| Jun 30, 2022 | 126.08% |
| Sep 30, 2021 | 123.80% |
| Jun 30, 2021 | 3.62% |
| Sep 30, 2020 | -100.37% |
| Jun 30, 2020 | -89.54% |
| Sep 30, 2019 | 135.87% |
| Jun 30, 2019 | 106.57% |
| Sep 30, 2018 | 98.27% |
| Jun 30, 2018 | -53.60% |
| Sep 30, 2017 | -205.05% |
| Jun 30, 2017 | 113.80% |
| Mar 31, 2017 | -164.59% |
| Dec 31, 2016 | 178.54% |